Global Pharmaceutical Softgel Capsules Market Size By Type (Analgesics, Steroids), By Application (Application 1, Application 2), By Region, And Segment Forecasts, 2023 to 2032

The Global Pharmaceutical Softgel Capsules Market was valued at USD 7.6 billion in 2023 and is projected to reach USD 13.9 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. This market is witnessing robust growth driven by the increasing demand for advanced drug delivery systems, rising prevalence of chronic diseases, and the preference for softgel capsules due to their ease of swallowing and higher bioavailability. Pharmaceutical companies are increasingly adopting softgel capsules to enhance patient compliance, especially for elderly and pediatric populations.

Drivers:

1. Growing Demand for Targeted Drug Delivery:

Softgel capsules provide efficient drug absorption and bioavailability, which are essential for targeted therapies. This makes them highly preferred for therapeutic areas like cardiology, oncology, and central nervous system disorders.

2. Rising Geriatric and Pediatric Populations:

The elderly and children often face difficulties swallowing tablets or hard capsules. Softgels offer a smooth, easy-to-swallow alternative, increasing their adoption in over-the-counter (OTC) and prescription medications.

3. Expansion of Nutraceutical and Dietary Supplement Applications:

Pharmaceutical softgel capsules are also widely used in nutraceuticals, leveraging consumer interest in preventive healthcare. The integration of vitamins, omega-3s, and herbal extracts in softgel format is contributing significantly to market growth.

Restraints:

1. High Production Costs:

Softgel manufacturing involves complex and expensive processes including gelatin melting, encapsulation, drying, and quality assurance, which can increase production costs and limit accessibility for smaller pharmaceutical manufacturers.

2. Regulatory and Compliance Challenges:

The stringent regulations regarding gelatin sourcing, encapsulation material standards, and stability testing across different regions may hinder new product launches and slow market entry.

Opportunity:

1. Innovations in Non-Gelatin and Plant-Based Softgels:

With increasing consumer awareness around sustainability and dietary restrictions, there is a growing opportunity for plant-based and non-animal gelatin softgel capsules, especially for vegetarian and vegan consumers.

2. Rising Demand in Emerging Markets:

Emerging economies in Asia-Pacific and Latin America are witnessing increased healthcare expenditures, better access to medication, and a growing pharmaceutical industry, which offers substantial growth potential for softgel capsule adoption.

Market by System Type Insights:

By system type, the Gelatin-based Softgel Capsules segment held the dominant market share in 2023 due to their established utility, affordability, and adaptability to a wide range of drug formulations. However, Non-Gelatin (Vegetarian/Vegan) Softgels are expected to witness the highest CAGR during the forecast period owing to the rise in plant-based consumer preferences and regulatory acceptance.

Market by End-use Insights:

Based on end-use, the Pharmaceutical Companies segment led the market in 2023, driven by increased drug development activity and the need for innovative oral dosage forms. Nutraceutical Manufacturers are also emerging as a high-growth end-user segment, particularly in developed economies where consumer awareness of preventive health is high.

Market by Regional Insights:

Geographically, North America dominated the market in 2023, supported by advanced pharmaceutical R&D, strong regulatory infrastructure, and high consumer adoption of OTC softgels. However, Asia-Pacific is poised to be the fastest-growing region through 2031 due to increasing healthcare investment, expanding pharmaceutical manufacturing capabilities, and rising demand for affordable therapeutics.

Competitive Scenario:

Key players operating in the Global Pharmaceutical Softgel Capsules Market include:

Catalent Inc.

BASF SE

Aenova Group

Lonza Group AG

EuroCaps Ltd.

Thermo Fisher Scientific

Sirio Pharma Co., Ltd.

Soft Gel Technologies Inc.

ProCaps Group

Captek Softgel International Inc.

These companies are investing in manufacturing expansion, clean-label innovations, and strategic collaborations to strengthen their global footprint and cater to evolving consumer and regulatory demands.

Scope of Work – Global Pharmaceutical Softgel Capsules Market

Key Market Developments:

2023: Catalent Inc. opened a new production line for plant-based softgel capsules at its European facility, expanding its vegetarian supplement offerings.

2024: Lonza Group AG announced a partnership with a major Asian pharmaceutical company to localize softgel capsule manufacturing in Southeast Asia.

2025: BASF SE introduced a bio-based softgel capsule material designed to improve shelf life and environmental sustainability.

FAQs:

1) What is the current market size of the Global Pharmaceutical Softgel Capsules Market?

The market was valued at USD 7.6 billion in 2023.

2) What is the major growth driver of the Global Pharmaceutical Softgel Capsules Market?

The primary growth driver is the increasing demand for targeted drug delivery and patient-friendly dosage forms.

3) Which is the largest region during the forecast period in the Global Pharmaceutical Softgel Capsules Market?

North America accounted for the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Pharmaceutical Softgel Capsules Market?

Gelatin-based softgel capsules dominated the market by system type in 2023.

5) Who are the key market players in the Global Pharmaceutical Softgel Capsules Market?

Leading players include Catalent Inc., Lonza Group AG, BASF SE, Aenova Group, and Thermo Fisher Scientific.